RGT — Argent BioPharma Cashflow Statement
0.000.00%
- AU$3.56m
- AU$3.48m
- AU$0.16m
Annual cashflow statement for Argent BioPharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -4.24 | -1.9 | -2.54 | -3.3 | -0.318 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -12.2 | -12 | -14.7 | -9.28 | -4.03 |
| Capital Expenditures | -2.69 | -0.19 | -0.14 | -0.002 | -0.002 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.58 | 0.796 | — | 0.211 | 0.001 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.11 | 0.606 | -0.14 | 0.209 | -0.001 |
| Financing Cash Flow Items | -0.703 | -0.102 | -0.437 | -0.568 | -0.011 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.74 | 9.73 | 15.3 | 9.39 | 3.14 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -3.55 | -1.65 | 0.463 | 0.322 | -0.883 |